Extending the chimeric receptor-based T-cell targeting strategy to solid tumors.
The adoptive transfer of T cells expressing chimeric antigen receptors (CARs) has emerged as a promising immunotherapeutic strategy against cancer. Administering CAR-expressing T cells in combination with agents that promote the expression of CAR targets or optimize T-cell function within the tumor microenvironment may further improve the therapeutic potential of this approach.
Department of Pediatric Hematology and Oncology; University Children's Hospital Muenster; Muenster, Germany.
Claudia
C
Rossig
CD19; chimeric receptor; gangliosides; target antigen; tumor microenvironment